Research programme: GPCR targeting therapeutics - Heptares

Drug Profile

Research programme: GPCR targeting therapeutics - Heptares

Latest Information Update: 09 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Heptares Therapeutics
  • Developer Heptares Therapeutics; National Heart and Lung Institute; University of Cambridge
  • Class Anti-inflammatories; Antiasthmatics; Small molecules
  • Mechanism of Action G protein-coupled receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Asthma; Cardiovascular disorders; Immunological disorders; Inflammatory bowel diseases

Most Recent Events

  • 31 Jan 2017 Early research in Cardiovascular disorders in United Kingdom (unspecified route)
  • 02 Feb 2016 Early research in Asthma in USA, United Kingdom (unspecified route)
  • 02 Feb 2016 Early research in Immunological disorders in United Kingdom, USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top